ClinicalTrials.gg
CompletedNCT01978938Updated Jan 11, 2022Results posted

Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections

A Phase 3 interventional study of Eravacycline and Levofloxacin in cUTI, sponsored by Tetraphase Pharmaceuticals, Inc.. Completed at 99 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-11.

Sponsored by Tetraphase Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
908
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy and safety of eravacycline compared with levofloxacin in participants with complicated urinary tract infections (cUTI).

Read the detailed description

This study began with a 3-arm Lead-in portion to determine the oral (PO) dosing (200 or 250 milligrams [mg]) of eravacycline to be used with intravenously (IV) administered eravacycline for the Pivotal portion (2 arms). A PO dose of 200 mg was selected based on the unblinded Lead-in analysis.

02

Conditions studied

  • cUTI
03

In context

Lead sponsor

Tetraphase Pharmaceuticals, Inc. is the lead sponsor of 15 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants with either:

a. Pyelonephritis and normal urinary tract anatomy (approximately 50% of the total population), OR b. cUTI with at least 1 of the following conditions associated with a risk for developing cUTI: i. Indwelling urinary catheter ii. Urinary retention (approximately 100 milliliters of residual urine after voiding) iii. Neurogenic bladder iv. Partial obstructive uropathy (such as, nephrolithiasis, bladder stones, and ureteral strictures) v. Azotemia of renal origin (not congestive heart failure or volume related) such that the serum blood urea nitrogen (BUN) is elevated (>20 mg/deciliters) AND the serum BUN: creatinine ratio is \<15 vi. Surgically modified or abnormal urinary tract anatomy (such as, bladder diverticula, redundant urine collection system) EXCEPT surgery within the last month

Exclusion criteria

Exclusion Criteria:

  1. Concurrent use of non-study antibacterial drug therapy that would have a potential effect on outcome evaluations in participants with cUTI, including:
  1. Participants with a history of a levofloxacin-resistant urinary tract infection
  2. Likely to receive ongoing antibacterial drug prophylaxis prior to the late Post-Treatment visit (such as, participants with vesiculo-ureteral reflux)
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
908 participants (actual)

Study arms

  • Experimental
    Eravacycline

    Eravacycline was administered IV at a dose of 1.5 mg per kilogram (kg) of body weight every 24 hours (q24h). At minimum, the first 3 doses were administered IV. After an IV-to-PO transition, provided adequate clinical improvement, participants were administered 200 mg PO twice a day for a total therapy of 7 dosing cycles.

    Drug: Eravacycline

  • Active comparator
    Levofloxacin

    Levofloxacin (750 mg) was administered IV q24h. At minimum, the first 3 doses were administered IV. After an IV-to-PO transition, provided adequate clinical improvement, participants were administered 750 mg PO once a day for a total therapy of 7 dosing cycles.

    Drug: Levofloxacin

Interventions

06

What researchers measure

Primary outcomes

  1. Participants In The Microbiological Intent-To-Treat (Micro-ITT) Population With A Responder Outcome At The Post-Treatment (PT) Visit

    This was the primary outcome measure for the Food and Drug Administration (FDA). The primary objective was to demonstrate the non-inferiority (NI) of eravacycline to levofloxacin in responder outcome, which was derived from both clinical and microbiological responses, in the micro-ITT population. Clinical responses were either cure, failure, or indeterminate/missing; microbiological responses were characterized programmatically as either success, failure, or indeterminate/missing. Clinical cure was defined as complete resolution or significant improvement of signs or symptoms of the infection; microbiological success was a reduction of the baseline pathogen(s) to \<10\^4 colony-forming units/milliliter (CFU/mL). An outcome of Responder required a clinical response of cure and a microbiological response of success. Any other combination of the clinical and microbiological responses was considered either Non-responder or Indeterminate.

    Time frame: PT Visit

Secondary outcomes

  1. Participants In The Microbiological Modified ITT (Micro-MITT) Population With A Microbiological Response

    This outcome measure (FDA and the European Medicines Agency \[EMA\]) compared the microbiological responses of eravacycline to levofloxacin for both treatment groups in the micro-MITT population. Responses were success, failure, or indeterminate/missing. Success was considered a reduction of the baseline pathogen(s) to \<10\^4 CFU/mL. Failure required blood cultures at or beyond end of therapy (EOT) to be positive for baseline pathogen(s), or urine culture to grow ≥10\^4 CFU/mL of the baseline pathogen(s). Indeterminate/missing indicated no interpretable culture data available.

    Time frame: PT Visit

  2. Participants In The Microbiologically Evaluable (ME) Population With A Microbiological Response

    This outcome measure (FDA and EMA) compared the microbiological responses of eravacycline to levofloxacin for both treatment groups in the ME population. Responses were either success or failure. Indeterminate/missing responses were not included. Success was considered a reduction of the baseline pathogen(s) to \<10\^4 CFU/mL. Failure required blood cultures at or beyond EOT to be positive for baseline pathogen(s), or urine culture to grow ≥10\^4 CFU/mL of the baseline pathogen(s). Indeterminate/missing indicated no interpretable culture data available. Populations: ME, all micro-ITT and clinically-evaluable (CE) participants with a suitable urine specimen and an interpretable urine culture; micro-ITT, all participants with ≥1 baseline bacterial pathogen from a urine or blood culture that caused a UTI against which eravacycline had expected antibacterial activity; ITT, all randomized participants, regardless of receiving study drug or not.

    Time frame: PT Visit

07

Results

Posted Dec 11, 2018

Participant flow

Participants with a diagnosis of complicated urinary tract infection (cUTI), including participants with acute pyelonephritis, were recruited into this study.

Participant flow — Overall Study
MilestoneEravacyclineLevofloxacin
Started455453
Received at least 1 dose of study drug454451
Completed432439
Not completed2314
Withdrew: Lost to follow-up126
Withdrew: Withdrawal by subject84
Withdrew: Adverse event, non-fatal21
Withdrew: Participant noncompliance11
Withdrew: Did not meet inclusion criteria01
Withdrew: Previously scheduled procedure01

Outcome measures

PrimaryParticipants In The Microbiological Intent-To-Treat (Micro-ITT) Population With A Responder Outcome At The Post-Treatment (PT) Visit

This was the primary outcome measure for the Food and Drug Administration (FDA). The primary objective was to demonstrate the non-inferiority (NI) of eravacycline to levofloxacin in responder outcome, which was derived from both clinical and microbiological responses, in the micro-ITT population. Clinical responses were either cure, failure, or indeterminate/missing; microbiological responses were characterized programmatically as either success, failure, or indeterminate/missing. Clinical cure was defined as complete resolution or significant improvement of signs or symptoms of the infection; microbiological success was a reduction of the baseline pathogen(s) to \<10\^4 colony-forming units/milliliter (CFU/mL). An outcome of Responder required a clinical response of cure and a microbiological response of success. Any other combination of the clinical and microbiological responses was considered either Non-responder or Indeterminate.

Time frame:
PT Visit
Reported as:
Count of participants · Participants
Participants In The Microbiological Intent-To-Treat (Micro-ITT) Population With A Responder Outcome At The Post-Treatment (PT) Visit
ParticipantsEravacyclineLevofloxacin
Responder180202
Non-responder10091
Indeterminate189
Statistical analysis
  • Eravacycline vs Levofloxacin · Treatment difference: -6.5 · 95% CI -14.1 to 1.2
SecondaryParticipants In The Microbiological Modified ITT (Micro-MITT) Population With A Microbiological Response

This outcome measure (FDA and the European Medicines Agency \[EMA\]) compared the microbiological responses of eravacycline to levofloxacin for both treatment groups in the micro-MITT population. Responses were success, failure, or indeterminate/missing. Success was considered a reduction of the baseline pathogen(s) to \<10\^4 CFU/mL. Failure required blood cultures at or beyond end of therapy (EOT) to be positive for baseline pathogen(s), or urine culture to grow ≥10\^4 CFU/mL of the baseline pathogen(s). Indeterminate/missing indicated no interpretable culture data available.

Time frame:
PT Visit
Reported as:
Count of participants · Participants
Participants In The Microbiological Modified ITT (Micro-MITT) Population With A Microbiological Response
ParticipantsEravacyclineLevofloxacin
Success194213
Failure8578
Indeterminate/missing1811
SecondaryParticipants In The Microbiologically Evaluable (ME) Population With A Microbiological Response

This outcome measure (FDA and EMA) compared the microbiological responses of eravacycline to levofloxacin for both treatment groups in the ME population. Responses were either success or failure. Indeterminate/missing responses were not included. Success was considered a reduction of the baseline pathogen(s) to \<10\^4 CFU/mL. Failure required blood cultures at or beyond EOT to be positive for baseline pathogen(s), or urine culture to grow ≥10\^4 CFU/mL of the baseline pathogen(s). Indeterminate/missing indicated no interpretable culture data available. Populations: ME, all micro-ITT and clinically-evaluable (CE) participants with a suitable urine specimen and an interpretable urine culture; micro-ITT, all participants with ≥1 baseline bacterial pathogen from a urine or blood culture that caused a UTI against which eravacycline had expected antibacterial activity; ITT, all randomized participants, regardless of receiving study drug or not.

Time frame:
PT Visit
Reported as:
Count of participants · Participants
Participants In The Microbiologically Evaluable (ME) Population With A Microbiological Response
ParticipantsEravacyclineLevofloxacin
Success180203
Failure7573

Adverse events

Collected over The time frame for adverse event reporting was from the first dose of study drug through 30 days after the last dose of study drug or the late post-treatment visit (whichever was later).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eravacycline1/455 (0.2%)7/455 (1.5%)129/455 (28.4%)
Levofloxacin0/450 (0%)6/450 (1.3%)26/450 (5.8%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventEravacyclineLevofloxacin
Pericardial effusionCardiac disorders0/4551/450
DiarrhoeaGastrointestinal disorders0/4551/450
OrchitisInfections and infestations0/4551/450
PneumoniaInfections and infestations0/4551/450
Psoas abscessInfections and infestations0/4551/450
Urinary retentionRenal and urinary disorders0/4551/450
Disseminated intravascular coagulationBlood and lymphatic system disorders1/4550/450
Pancreatitis acuteGastrointestinal disorders1/4550/450
Suicide attemptPsychiatric disorders1/4550/450
Renal colicRenal and urinary disorders1/4550/450
Most frequent other events
Most frequent other events
EventEravacyclineLevofloxacin
NauseaGastrointestinal disorders82/45514/450
VomitingGastrointestinal disorders33/4556/450
HeadacheNervous system disorders14/4556/450

Baseline characteristics

The intent-to-treat (ITT) population consisted of all randomized participants regardless of whether or not the participant received study drug.

Age, Categorical
Age, Categorical(Participants)EravacyclineLevofloxacinTotal
<=18 years000
Between 18 and 65 years291301592
>=65 years164152316
Age, Continuous
Age, Continuous(years)EravacyclineLevofloxacinTotal
Mean53.7 ± 18.8251.7 ± 19.8152.7 ± 19.3
Sex: Female, Male
Sex: Female, Male(Participants)EravacyclineLevofloxacinTotal
Female291302593
Male164151315
08

Study locations

99 sites
  • San Diego Clinical Trials
    San Diego, California, United States
  • Harbor-UCLA Medical Center
    Torrance, California, United States
  • Tampa General Hospital
    Tampa, Florida, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Sunrise Hospital and Medical Centre
    Las Vegas, Nevada 89109, United States
  • Columbus Regional Research Institute
    Columbus, Ohio, United States
  • Multiprofile Hospital for Active Treatment "Dr. Tota Venkova", Gabrovo, Department of Nephrology
    Gabrovo, Bulgaria
  • Multiprofile Hospital for Active Treatment "Dr. Stamen Iliev", Montana, Department of Nephrology and Dialysis
    Montana, Bulgaria
  • University Multiprofile Hospital for Active Treatment "Dr. Georgi Stranski", Pleven, Urology Clinic
    Pleven, Bulgaria
  • Multiprofile Hospital for Active Treatment, Ruse, Department of Urology
    Rousse, Bulgaria
  • Multiprofile Hospital for Active Treatment, Sofia at Military Medical Academy, General Urology Clinic
    Sofia, Bulgaria
  • University Multiprofile Hospital for Active Treatment "Aleksandrovska", Sofia, Department of Laparoscopic Urology
    Sofia, Bulgaria
  • University Multiprofile Hospital for Active Treatment and Emergency Medicine "N.I. Pirogov", Sofia, Urology Clinic
    Sofia, Bulgaria
  • Multiprofile Regional Hospital for Active Treatment "Dr. Stefan Cherkezov", Veliko Tarnovo, Department of Urology
    Veliko Tarnovo, Bulgaria
  • Fundacion Cardiomet
    Armenia, Colombia
  • De la Costa Clinic. Ltd. Research Centre
    Barranquilla, Colombia
  • University Hospital Brno, Clinic of Urology
    Brno, Czechia
  • University Hospital Hradec Kralove, Clinic of Urology
    Hradec Kralove, Czechia
  • Hospital Novy Jicin, Department of Urology
    Novy Jicin, Czechia
  • University Hospital Olomouc
    Olomouc, Czechia
  • Thomayer Hospital, Department of Urology
    Prague, Czechia
  • East Viru Central Hospital, Surgery Clinic
    Kohtla-Jarve, Estonia
  • East Tallinn Central Hospital, Department of Internal Medicine
    Tallinn, Estonia
  • West Tallinn Central Hospital, Department of Urology
    Tallinn, Estonia
  • Tartu University Hospital, Surgery Clinic, Department of Urology and Renal Transplantation
    Tartu, Estonia
  • Western Georgia National Medical Center
    Kutaisi, Georgia
  • Aversi Clinic
    Tbilisi, Georgia
  • Modern Medical Technologies - Guram Karazanashvili's clinic
    Tbilisi, Georgia
  • Research Institute of Clinical Medicine
    Tbilisi, Georgia
  • Tsulukidze National Center of Urology
    Tbilisi, Georgia
  • Evaggelismos Hospital
    Kolonaki, Greece
  • Papageorgiou General Hospital
    Thessaloníki, Greece
  • Principal SMO Kft.
    Baja, Hungary
  • Jahn Ferenc South Pest Hospital, Department of Urology
    Budapest, Hungary
  • Petz Aladar County Teaching Hospital, Department of Urology
    Gyor, Hungary
  • Elisabeth Teaching Hospital and Rehabilitation Institute of Sopron, Department of Urology
    Sopron, Hungary
  • Csongrad County Dr. Bugyi Istvan Hospital, Department of Urology
    Szentes, Hungary
  • St. Borbala Hospital, Department of Urology
    Tatabanya, Hungary
  • Zion Medical Center
    Haifa, Israel
  • Hospital Mater Domini
    Castellanza, Italy
  • Liepajas Regional Hospital
    Liepaja, Latvia
  • P. Stradins Clinical University Hospital
    Riga, Latvia
  • Riga East University Hospital, LLC
    Riga, Latvia
  • SIA 'URO' Clinic
    Riga, Latvia
  • Vidzemes Hospital
    Valmiera, Latvia
  • Hospital Civil Fray Antonio Alcalde
    Guadalajara, Mexico
  • Hospital Civil Guadalajara Dr. Juan I. Mendoza
    Guadalajara, Mexico
  • National Scientific Practical Center for Emergency Medicine, Department of Urology
    Chisinau, Moldova, Republic of
  • Republican Clinical Hospital, Department of Urology
    Chisinau, Moldova, Republic of
  • Boni Fratres Catoviensis Sp. z o.o., Department of Internal Diseases with Cardiologic Diagnostics Unit
    Katowice, Poland
  • Military Medical Academy University Teaching Hospital - Central Veterans' Hospital, Clinical and Didactic Center of the Medical University of Lodz, Teaching Department of Nephrology, Hypertension and Renal Transplantation
    Lodz, Poland
  • Medicome Sp. z o.o.
    Oswiecim, Poland
  • HEUREKA Hanna Szalecka
    Piaseczno, Poland
  • Pope John Paul 2nd Independent Public Provincial Hospital
    Zamość, Poland
  • Emergency Clinical County Hospital Brasov
    Brasov, Romania
  • "Prof. Dr. Th. Burghele" Clinical Hospital
    Bucharest, Romania
  • Delta Hospital
    Bucharest, Romania
  • Craiova Emergency Clinical County Hospital
    Craiova, Romania
  • Clinical Hospital "Dr. C. I. Parhon"
    Iași, Romania
  • Oradea Clinical Municipal Hospital "Dr. Gavril Curteanu"
    Oradea, Romania
  • Sibiu County Emergency Clinical Hospital
    Sibiu, Romania
  • Central Clinical Hospital of Civil Aviation
    Moscow, Russian Federation
  • City Clinical Hospital #57 under Moscow Healthcare Department
    Moscow, Russian Federation
  • Federal Clinical Center for High Medical Technologies
    Moscow, Russian Federation
  • City Clinical Hospital of Emergency Care #2
    Novosibirsk, Russian Federation
  • Penza Regional Clinical Hospital n.a. N.N. Burdenko
    Penza, Russian Federation
  • Rostov State Medical University
    Rostov-on-Don, Russian Federation
  • North-Western State Medical University n.a. I.I. Mechnikov
    Saint Petersburg, Russian Federation
  • Saint-Petersburg Scientific Research Institute for Phthisiopulmonology
    Saint Petersburg, Russian Federation
  • St. Petersburg Clinical Hospital under the Russian Academy of Sciences
    Saint Petersburg, Russian Federation
  • St. Petersburg State Healthcare Institution: City Hospital #15
    Saint Petersburg, Russian Federation
  • St. Petersburg State Healthcare Institution: St. George the Martyr City Hospital
    Saint Petersburg, Russian Federation
  • St. Petersburg State-Funded Healthcare Institution: City Hospital #26
    Saint Petersburg, Russian Federation
  • Saratov State Medical University n.a. V.I. Razumovsky
    Saratov, Russian Federation
  • Smolensk Regional Clinical Hospital
    Smolensk, Russian Federation
  • Novgorod Regional Clinical Hospital
    Veliky Novgorod, Russian Federation
  • Vsevolozhsk Clinical Central District Hospital
    Vsevolozhsk, Russian Federation
  • Lakeview Hospital
    Benoni, South Africa
  • Clinresco Centres
    Kempton Park, South Africa
  • Mzansi Ethical Research Centre
    Middleburg, South Africa
  • St. Georges Hospital
    Port Elizabeth, South Africa
  • Regional Municipal Institution "Chernivtsi Regional Hospital"
    Chernivtsi, Ukraine
  • Dnipropetrovsk City Multispecialty Clinical Hospital #4
    Dnipropetrovsk, Ukraine
  • Dnipropetrovsk I.I. Mechnikov Regional Clinical Hospital
    Dnipropetrovsk, Ukraine
  • Ivano-Frankivsk City Clinical Hospital #1
    Ivano-Frankivs'k, Ukraine
  • Ivano-Frankivsk Regional Clinical Hospital
    Ivano-Frankivs'k, Ukraine
  • O.I. Meschaninov Clinical Hospital of Emergency and Urgent Medical Care
    Kharkiv, Ukraine
  • Shapoval Regional Clinical Center of Urology and Nephrology
    Kharkiv, Ukraine
  • Khmelnytskyi Regional Hospital
    Khmel'nyts'kyy, Ukraine
  • Institute of Urology
    Kyiv, Ukraine
  • Lviv Regional Clinical Hospital
    L'viv, Ukraine
  • Volyn Regional Clinical Hospital
    Luts'k, Ukraine
  • Mykolaiv Regional Hospital, Center for Nephrology and Dialysis
    Mykolaiv, Ukraine
  • City Clinical Hospital #10, Urology Department #1
    Odesa, Ukraine
  • Odesa Regional Clinical Hospital
    Odessa, Ukraine
  • Poltava M.V. Sklifosovskyi Regional Clinical Hospital
    Poltava, Ukraine
  • State Institution: Uzhhorod Railway Station Clinical Hospital under State Territorial Industry-Specific Association:Lviv Railway
    Uzhhorod, Ukraine
  • Vinnytsia M.I. Pyrohov Regional Clinical Hospital
    Vinnytsya, Ukraine
  • Municipal Institution "Zaporizhzhia Reqional Clinical Hospital" of Zaporizhzhia Regional Councill
    Zaporizhzhya, Ukraine
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2014 to primary completion in Jun 2015, 7 months.

Results were first posted in Dec 2018, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2013
First posted
Nov 8, 2013
StartActual
Oct 6, 2014
Primary completionActual
Jun 3, 2015
CompletionActual
Aug 21, 2015
Results first posted
Dec 11, 2018
Last update
Jan 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01978938
Lead sponsor
Tetraphase Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Nov 8, 2013
Start date
Oct 6, 2014
Primary completion
Jun 3, 2015
Completion
Aug 21, 2015
Results posted
Dec 11, 2018
Last update
Jan 11, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eravacycline

Start the discussion